This won't cheer you up about "social anxiety disorder," I'm sure, but it's necessary for us to know what is real and what is not, so we don't get sidetracked into treatments that may not be beneficial
Honestly, I believe that those of us with depression and shyness (here I am substituting the good old generic term for "social anxiety disorder," before the advent of drug branding campaigns - see below.) are the ones who perceive the realities of this world best, not those who don't. I would not wish life in my environment at this time on any being. When I lived abroad in other cultures, I was not depressed.
http://seroxatsecrets.wordpress.com/201 ... ing-works/The article above is entitled "Branding Disease - how drug marketing works" by Dr. Carl Elliott. He demonstrates how one drug company used a marketing campaign to reshape "shyness" into "social anxiety disorder" in order to market their drug. In part, the article says...
"Another good candidate for branding is a condition that can be plausibly portrayed as under-diagnosed. Branding such a condition assures potential patients that they are part of a large and credible community of sufferers. For example, in 1999, the FDA approved the antidepressant Paxil for the treatment of “social anxiety disorder,” a condition previously known as “shyness.”
See more CNN.com opinion articles
In order to convince shy people they had social anxiety disorder, GlaxoSmithKline, the maker of Paxil, hired a PR firm called Cohn and Wolfe. Cohn and Wolfe put together a public awareness campaign called “Imagine being allergic to people,” which was allegedly sponsored by a group called the “Social Anxiety Disorders Coalition.”
GlaxoSmithKline also recruited celebrities like Ricky Williams, the NFL running back, and paid them to give interviews to the press about their own social anxiety disorder. Finally, they hired academic psychiatrists working on social anxiety disorder and sent them out on the lecture circuit in the top 25 media markets.
The results were remarkable. In the two years before Paxil was approved for social anxiety, there were only about 50 references to social anxiety disorder in the press. But in 1999, during the PR campaign, there were over a billion references.
Within two years Paxil had become the seventh most profitable drug in America, and Cohn and Wolfe had picked up an award for the best PR campaign of 1999. Today, social anxiety disorder, far from being rare, is often described as the third most common mental illness in the world.
It is hard to brand a disease without the help of physicians, of course. So drug companies typically recruit academic “thought leaders” to write and speak about any new conditions they are trying to introduce. It also helps if the physicians believe the branded condition is dangerous."